Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro

Molecular Pharmacology

Volumn 63, Issue 6, 2003, Pages 1248-1255

  Chinje, Edwin C ^a   Cowen, Rachel L ^a   Feng, Jian ^b   Sharma, Sanjeev P ^a   Wind, Natasha S ^a   Harris, Adrian L ^c   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHENGDU UNIVERSITY   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; ELONGATION FACTOR 1ALPHA; FREE RADICAL; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; PUROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CATALYSIS; CELL CLONE; CENTRIFUGATION; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; FREE RADICALS; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PLASMIDS; SUBCELLULAR FRACTIONS; TRANSFECTION; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0038779269     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.6.1248     Document Type: Article

References (40)

1. Biedermann KA, Wang J, Graham RP and Brown JM (1991) SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer 63:358-362.
2. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR and Snyder SH (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature (Lond) 351:714-718.
3. Brown JM (1993) SR4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170.
4. Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL and Stratford IJ (1999) Does reductive metabolism predict response to tirapazamine (SR4233) in human non-small-cell lung cancer cell lines? Br J Cancer 81:1127-1133.
5. Chinje EC, Williams KJ, Telfer BA, Wood PJ, van der Kogel AJ and Stratford IJ (2002) 17β-oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer 86:136-142.
6. Cobbs CS, Brenman JE, Aldape KD, Bredt DS and Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumours. Cancer Res 55:727-730.
7. Daniels JS and Gates KS (1996) DNA cleavage by the anti-tumour agent 3-amino 1,2,4-benzotriazine 1,4-dioxide (SR4233): evidence of involvement of hydroxyl radicals. J Am Chem Soc 118:3380-3385.
8. Daniels JS, Gates KS, Tronche C and Greenberg MM (1998) Direct evidence for bimodal DNA damage induced by tirapazamine. Chem Res Toxicol 11:1254-1257.
9. Delahoussaye YM, Evans JW and Brown JM (2001) Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 62:1201-1209.
10. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC and Fisher B (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18:1254-1259.
11. Elwell JH, Siim BG, Evans JW and Brown JM (1997) Adaptation of human cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 54:249-257.
12. Evans JW, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58:2098-2101.
13. Gallo O, Sardi I, Masini M and Franchi A (1999) Re: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 91:1509-1511.
14. Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH and Gumerlock PH (2002) Tirapazamine: prototype for a novel class of therapeutic agents targeting tumour hypoxia. Semin Oncol 29:102-109.
15. Garner AP, Paine MJI, Rodriguez-Crespo I, Chinje EC, Ortiz de Montellano P, Stratford IJ, Tew DG, and Wolf CR (1999) Nitric oxide synthases catalyse the activation of redox cycling and bioreductive anticancer agents. Cancer Res 59: 1929-1934.
16. Halliwell B and Gutteridge JMC (1999) Free Radicals in Biology and Medicine, 3rd ed, Oxford University Press, Oxford.
17. Henderson LM and Chappell JB (1993) Dihydrorhodamine 123: a fluorescent probe for superoxide generation? Eur J Biochem 217:973-980.
18. Hwang JT, Greenberg MM, Fuchs T and Gates KS (1999) Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions Biochemistry, 38: 14248-14255.
19. Jones GDD and Weinfield M (1996) Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res 56:1584-1590.
20. Kotandeniya D, Ganley B and Gates KS (2002) Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). Bioorg Med Chem Lett 12:2325-2329.
21. Laderoute K, Wardman P, Rauth AM (1988) Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR4233). Biochem Pharmacol 37:1487-1495.
22. Lee DJ, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E, and Groves E (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42:811-815.
23. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, and Bridson PK (1991) Microsomal reduction of 3-amino 1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40:440-445.
24. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, and Varesio L (1995) A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683-1693.
25. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug tirapazamine (SR4233) Br J Cancer 72:1144-1150.
26. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, and Stratford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069 Br J Cancer 76:1338-1347.
27. Peters KB, Wang H, Brown JM and Iliakis G (2001) Inhibition of DNA replication by tirapazamine. Cancer Res 61:5425-5431.
28. Robertson N, Haigh A, Adams GE and Stratford IJ (1994) Factors affecting sensitivity to EO9 in rodent and human tumour cell lines in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A:1013-1019.
29. Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS and Weissler MC (1995) Immunohistochemical characterization ofnitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 113:541-549.
30. Saunders MP, Patterson AV, Chinje EC, Harris AL and Stratford IJ (2000) NADPH: cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 82:651-656.
31. Siim BG, van Zijl PL and Brown JM (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73:952-960.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
33. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA and Weiss RM (1999) Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urology 161:630-634.
34. Thomsen LL, Lawton FG, Knowles RG, Beesley JF, Riveros-Moreno V and Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54:1352-1354.
35. Thomsen LL and Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17:107-118.
36. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41-44.
37. Wang J, Biedermann KA and Brown JM (1992) Repair of DNA and chromosome breaks in cells exposed to SR4233 under hypoxia or to ionizing radiation. Cancer Res 52:4473-4477.
38. Wang J, Biedermann KA, Wolf CR and Brown JM (1993) Metabolism of the bioreductive drug cytotoxin SR4233 by tumour cells: enzymatic studies. Br J Cancer 67:321-325.
39. van den Hoff MJ, Moorman AF and Lamers WH (1992) Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res 20:2902.
40. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, et al. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18: 1351-1359.